Genmab Cash Pile To Grow With Another Darzalex OK
The Danish biotech will be getting more revenues from its J&J-partnered multiple myeloma blockbuster following a new US approval. Analysts are impressed with the way Genmab is spending the money.

The Danish biotech will be getting more revenues from its J&J-partnered multiple myeloma blockbuster following a new US approval. Analysts are impressed with the way Genmab is spending the money.